Abstract

The benefits of SGLT2 inhibitors in heart failure may be mediated by the inhibition of sodium-hydrogen exchange rather than the effect on glucose reabsorption. This hypothesis has important implications for the design and analysis of large-scale outcomes trials involving diabetic or nondiabetic patients with chronic heart failure.

Keywords

EmpagliflozinMedicineHeart failureCardiologyEjection fractionInternal medicineMyocardial infarctionType 2 diabetesHeart failure with preserved ejection fractionDiabetes mellitusDapagliflozinEndocrinology

Affiliated Institutions

Related Publications

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)

John J.V. McMurray , David L. DeMets , Silvio E. Inzucchi +9 more

Background Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes wh...

2019 European Journal of Heart Failure 430 citations

Publication Info

Year
2017
Type
article
Volume
2
Issue
9
Pages
1025-1025
Citations
328
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

328
OpenAlex

Cite This

Milton Packer, Stefan D. Anker, Javed Butler et al. (2017). Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure. JAMA Cardiology , 2 (9) , 1025-1025. https://doi.org/10.1001/jamacardio.2017.2275

Identifiers

DOI
10.1001/jamacardio.2017.2275